Topical 15% Trichloroacetic Acid Versus Silver Nitrate Cauterization in the Management of Idiopathic Childhood Epistaxis: A Prospective Double-Blinded, Randomized Clinical Trial
Launched by YOUSSEF ZAKI · Feb 19, 2025
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
Epistaxis is a very distressing complaint in otorhinolaryngology that affects nearly 10-12% of the population worldwide . Epistaxis in children is even more common. Approximately half of the children had one or more episodes of epistaxis by the age of 10 .
The source of epistaxis may be anterior or posterior; in children, epistaxis is commonly anterior, originating mainly from the anterior part of the nasal septum called Little's area, in which a confluence of veins named Kiesselbach's plexus is the main area to blame . Anterior epistaxis is commonly related to local trauma, such as nose p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients aged between 4 and 16 years at least once weekly in the last 4 weeks with visible anterior bleeding sources either unilateral or bilateral from Little's area were included in the study.
- Exclusion Criteria:
- • All patients with documented coagulopathy, those with sinonasal or nasopharyngeal masses, those with active rhinosinusitis or severe allergic rhinitis or severe septal deviation
About Youssef Zaki
Youssef Zaki is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on improving patient outcomes, the organization collaborates with leading healthcare professionals and institutions to design and conduct rigorous clinical trials across various therapeutic areas. Youssef Zaki emphasizes ethical practices, regulatory compliance, and the integration of patient perspectives, ensuring that each study is conducted with the highest standards of quality and integrity. Through its strategic partnerships and commitment to scientific excellence, Youssef Zaki aims to contribute significantly to the development of safe and effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kafrelsheikh, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported